Groupama Asset Managment Reduces Stake in Gilead Sciences, Inc. $GILD

Key Points

• Groupama Asset Management has reduced its stake in Gilead Sciences by 11.5%, owning 47,925 shares valued at approximately $5.36 million after selling 6,247 shares in the first quarter.
• Gilead Sciences reported a net margin of 21.86% and exceeded analysts' expectations with a $7.08 billion revenue for the quarter.
• Gilead announced a quarterly dividend of $0.79 per share, with a yield of 2.7% and a payout ratio of 62.95%.

Groupama Asset Managment lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 47,925 shares of the biopharmaceutical company's stock after selling 6,247 shares during the period. Groupama Asset Managment's holdings in Gilead Sciences were worth $5,358,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in GILD. Nissay Asset Management Corp Japan ADV boosted its holdings in shares of Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares in the last quarter. Golden State Wealth Management LLC raised its stake in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 109 shares in the last quarter. Mufg Securities Americas Inc. purchased a new stake in Gilead Sciences in the fourth quarter valued at $1,699,000. ASR Vermogensbeheer N.V. acquired a new position in Gilead Sciences in the first quarter valued at $11,688,000. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Gilead Sciences by 4.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock worth $32,827,000 after purchasing an additional 13,194 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 0.0%

Shares of NASDAQ:GILD opened at $117.98 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $74.34 and a fifty-two week high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm's 50-day simple moving average is $112.14 and its 200-day simple moving average is $108.71. The company has a market cap of $146.39 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 0.72 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the firm earned $2.01 earnings per share. The firm's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is currently 62.95%.

Insiders Place Their Bets

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the transaction, the chief financial officer directly owned 162,610 shares of the company's stock, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,000 shares of company stock worth $12,349,790. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Finally, Oppenheimer reduced their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and seven have given a Hold rating to the company's stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.